-- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013,…
MaaT PharmaAugust 31, 2020
-- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients…
MaaT PharmaAugust 28, 2020
La nouvelle campagne de collecte soutiendra le développement clinique futur du portefeuille de biothérapies à…
MaaT PharmaAugust 20, 2020
New collection campaign to support future clinical development of microbiome biotherapeutic product portfolio and to…
MaaT PharmaAugust 20, 2020
Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand,…
MaaT PharmaJuly 16, 2020
Lyon, France, May 28, 2020 – MaaT Pharma announced today that Savita Bernal, PhD, has…
MaaT PharmaMay 28, 2020
Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international…
nboutaouiMay 12, 2020
In response to the recent “FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation…
nboutaouiMarch 13, 2020
March 13th, 2020 MaaT Pharma – Information COVID-19 In the context of the COVID-19…
nboutaouiMarch 13, 2020